Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability)
"Anyone continuing to sell mass compounded tirzepatide or semaglutide products, including by referring to them as 'personalized,' 'tailored' or something similar, is breaking the law and putting patient safety at risk
These substitutions can affect drug stability, absorption, and may trigger allergic reactions or other adverse effects
Freezing breaks down the peptide structure in ways that are not visible to the eye
Insert the needle at a 45 to 90 degree angle, depending on how much subcutaneous fat is present at the site
doi:10.1016/S2213-8587(19)30084-1